• SPX
  • $5,893.62
  • 0.39 %
  • $23.00
  • DJI
  • $43,389.60
  • -0.13 %
  • -$55.39
  • N225
  • $38,513.08
  • 0.77 %
  • $292.45
  • FTSE
  • $8,109.32
  • 0.57 %
  • $45.71
  • IXIC
  • $18,791.81
  • 0.6 %
  • $111.69
Chromocell Therapeutics Corporation (CHRO) Stock Price, News & Analysis

Chromocell Therapeutics Corporation (CHRO) Stock Price, News & Analysis

Currency in USD Disclaimer

$0.63

-$0

(-0.16%)

Day's range
$0.63
Day's range
$0.69
50-day range
$0.52
Day's range
$1.11
  • Country: US
  • ISIN: N/A
52 wk range
$0.52
Day's range
$6
  • CEO: Mr. Francis Knuettel II, M.B.A.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -36.79
  • Piotroski Score 2.00
  • Grade N/A
  • Symbol (CHRO)
  • Company Chromocell Therapeutics Corporation
  • Price $0.63
  • Changes Percentage (-0.16%)
  • Change -$0
  • Day Low $0.63
  • Day High $0.69
  • Year High $6.00

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/12/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) $0.00
  • Trailing P/E Ratio N/A
  • Forward P/E Ratio N/A
  • P/E Growth N/A
  • Net Income $-7,380,793

Income Statement

Quarterly

Annual

Latest News of CHRO

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Chromocell Therapeutics Corporation Frequently Asked Questions

  • What is the Chromocell Therapeutics Corporation stock price today?

    Today's price of Chromocell Therapeutics Corporation is $0.63 — it has decreased by -0.16% in the past 24 hours. Watch Chromocell Therapeutics Corporation stock price performance more closely on the chart.

  • Does Chromocell Therapeutics Corporation release reports?

    Yes, you can track Chromocell Therapeutics Corporation's financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Chromocell Therapeutics Corporation stock forecast?

    Watch the Chromocell Therapeutics Corporation chart and read a more detailed Chromocell Therapeutics Corporation stock forecast to see what analysts suggest you do with its shares.

  • What is Chromocell Therapeutics Corporation stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on AMEX, exchange stock trades by Chromocell Therapeutics Corporation stock ticker.

  • How to buy Chromocell Therapeutics Corporation stocks?

    Like other stocks, CHRO shares are sold on stock exchanges such as AMEX. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Chromocell Therapeutics Corporation's EBITDA?

    Chromocell Therapeutics Corporation measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Chromocell Therapeutics Corporation’s financial statements.

  • What is the Chromocell Therapeutics Corporation's net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Chromocell Therapeutics Corporation stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Chromocell Therapeutics Corporation's financials relevant news, and technical analysis. Chromocell Therapeutics Corporation's technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Chromocell Therapeutics Corporation stock currently indicates a “sell” signal. For more insights, review Chromocell Therapeutics Corporation’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.